OUR PRODUCTS
Our Products
As a world-leader in biosimilars, we have one of the most
expansive and rapidly growing portfolios in the industry.
Samsung Bioepis has an extensive portfolio and pipeline of biosimilar medicines.
Etanercept Biosimilar
Infliximab
Biosimilar Adalimumab Biosimilar Trastuzumab Biosimilar Bevacizumab Biosimilar Ranibizumab Biosimilar
Biosimilar Adalimumab Biosimilar Trastuzumab Biosimilar Bevacizumab Biosimilar Ranibizumab Biosimilar
SB4
Etanercept Biosimilar
Approved by EC (Europe)
in Jan 2016 Approved by MFDS (KR)
in Sep 2015 Approved by HC (Canada)
in Aug 2016 Approved by TGA (Australia)
in Jul 2016 Approved by MoH (Israel)
in Jan 2019 Approved by ANVISA (Brazil)
in Dec 2017 Approved by Swissmedic
in Sep 2018 Approved by Medsafe
(New Zealand) in Feb 2019 Approved by FDA (US)
in Apr 2019 Approved by TFDA (Taiwan)
in Sep 2021
in Jan 2016 Approved by MFDS (KR)
in Sep 2015 Approved by HC (Canada)
in Aug 2016 Approved by TGA (Australia)
in Jul 2016 Approved by MoH (Israel)
in Jan 2019 Approved by ANVISA (Brazil)
in Dec 2017 Approved by Swissmedic
in Sep 2018 Approved by Medsafe
(New Zealand) in Feb 2019 Approved by FDA (US)
in Apr 2019 Approved by TFDA (Taiwan)
in Sep 2021
| Product Infomation | Reference Biologic | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ENBREL | |||||||||||||||
|
||||||||||||||||
SB2
Infliximab Biosimilar
| Product Infomation | Reference Biologic | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
REMICADE | ||||||||||||||
|
|||||||||||||||
SB5
Adalimumab Biosimilar
Approved by EC (Europe)
in Aug 2017 Approved by HC (Canada)
in May 2018 Approved by MFDS (KR)
in Sep 2017 Approved by TGA (Australia)
in Jan 2018 Approved by FDA (US)
in Jul 2019 Approved by Swissmedic
in Apr 2020 Approved by TFDA (Taiwan)
in Nov 2021 Approved by SFDA
(Saudi Arabia) in Aug 2021 Approved by MoH (Israel)
in Feb 2021
in Aug 2017 Approved by HC (Canada)
in May 2018 Approved by MFDS (KR)
in Sep 2017 Approved by TGA (Australia)
in Jan 2018 Approved by FDA (US)
in Jul 2019 Approved by Swissmedic
in Apr 2020 Approved by TFDA (Taiwan)
in Nov 2021 Approved by SFDA
(Saudi Arabia) in Aug 2021 Approved by MoH (Israel)
in Feb 2021
| Product Infomation | Reference Biologic | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
HUMIRA | ||||||||||
|
|||||||||||
SB3
Trastuzumab Biosimilar
| Product Infomation | Reference Biologic | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
HERCEPTIN | |||||||||||
|
||||||||||||
SB8
Bevacizumab Biosimilar
| Product Infomation | Reference Biologic | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
AVASTIN | |||||||||
|
||||||||||
SB11
Ranibizumab Biosimilar
| Product Infomation | Reference Biologic | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
LUCENTIS | |||||||||||
|
||||||||||||
